DiaMedica Therapeutics (DMAC) is expected to complete enrollment for an interim futility analysis of its phase 2/3 ReMEDy2 clinical trial, using DM199 for the treatment of patients with acute ischemic ...
(RTTNews) - Immunic, Inc. (IMUX) Tuesday announced positive outcome from the interim futility analysis of its Phase 3 ENSURE program evaluating the company's lead asset, IMU-838 for the treatment of ...
On Monday, Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational ...
Immunic (IMUX) announced the outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear receptor related 1, or Nurr1, activator, ...
Sorrento Therapeutics’ Phase II study of the tyrosine kinase inhibitor (TKI) STI-5656 (abivertinib) in hospitalised Covid-19 patients has enrolled 60 of its 80-patient target, said CEO Henry Ji. A ...
Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc [PH20]), a neonatal Fc receptor blocker, for the treatment of moderate to severe ...
PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of ...
--HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- --Company Plans to Request a Meeting with FDA in the First Quarter of 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results